MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Balance Sheets Overview
Current Ratio
404.06%
Quick Ratio
404.06%
Debt to Asset Ratio
24.15%
Unit: Thousand (K) dollars
Assets Breakdown
Cash and cash equivalents
Research and development tax cre...
Equipment, net
Others
Liabilities Breakdown
Additional paid-in capital
Accumulated deficit
Accounts payable and accrued lia...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
18,411
21,358
24,751
27,734
Research and development tax credit receivable
4,413
479
4,284
1,704
Other tax receivable
354
291
257
760
Prepaid expenses and other current assets
621
694
595
472
Total current assets
23,799
22,822
29,887
30,670
Equipment, net
1,262
903
955
878
Operating lease right of use asset
1,247
1,410
914
1,064
Other assets
537
683
595
746
Total assets
26,845
25,818
32,351
33,358
Accounts payable and accrued liabilities
5,053
4,659
7,768
6,875
Accounts payable and accrued liabilities related parties
25
25
25
25
Operating lease, current liabilities
812
704
623
457
Total current liabilities
5,890
5,388
8,416
7,357
Long-term operating lease liability
593
806
411
623
Total liabilities
6,483
6,194
8,827
7,980
Common stock, 0.001 par value, 200,000,000 shares authorized, 27,653,789 and 26,585,258 shares issued and outstanding, respectively
28
27
27
27
Additional paid-in capital
237,688
234,768
233,271
229,888
Subscription receivable
814
-
-
-
Accumulated other comprehensive loss
-823
-727
-737
-764
Accumulated deficit
-215,717
-214,444
-209,037
-203,773
Total stockholders equity
20,362
19,624
23,524
25,378
Total liabilities and stockholders equity
26,845
25,818
32,351
33,358
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Balance Sheets
Cash and cash
equivalents
$18,411K
(-44.83%↓ Y/Y)
Research and development
tax credit...
$4,413K
(174.95%↑ Y/Y)
Prepaid expenses and
other current assets
$621K
(22.97%↑ Y/Y)
Other tax receivable
$354K
(-35.64%↓ Y/Y)
Total current assets
$23,799K
(-33.95%↓ Y/Y)
Equipment, net
$1,262K
(78.75%↑ Y/Y)
Operating lease right of
use asset
$1,247K
(233.42%↑ Y/Y)
Other assets
$537K
(-5.79%↓ Y/Y)
Total assets
$26,845K
(-28.76%↓ Y/Y)
Total liabilities and
stockholders equity
$26,845K
(-28.76%↓ Y/Y)
Total stockholders
equity
$20,362K
(-29.46%↓ Y/Y)
Total liabilities
$6,483K
(-26.47%↓ Y/Y)
Accumulated deficit
-$215,717K
(-9.33%↓ Y/Y)
Accumulated other
comprehensive loss
-$823K
(-7.86%↓ Y/Y)
Subscription receivable
$814K
Additional paid-in capital
$237,688K
(4.75%↑ Y/Y)
Total current
liabilities
$5,890K
(-31.40%↓ Y/Y)
Long-term operating lease
liability
$593K
(156.71%↑ Y/Y)
Common stock, 0.001 par
value, 200,000,000...
$28K
(3.70%↑ Y/Y)
Accounts payable and
accrued liabilities
$5,053K
(-34.13%↓ Y/Y)
Operating lease, current
liabilities
$812K
(269.09%↑ Y/Y)
Accounts payable and
accrued liabilities ...
$25K
(-86.41%↓ Y/Y)
Buy us a coffee
Inmune Bio, Inc. (INMB)
Inmune Bio, Inc. (INMB)